Better Buy: CVS vs. Regeneron
Coming into 2020, there's no question that you would have been better off investing in Regeneron Pharmaceuticals (NASDAQ: REGN) than in CVS (NYSE: CVS). If you had spent $10,000 on each stock at the beginning of the year, you would have $8,762.50 as of Monday with CVS (including dividends) and $15,464.02 with Regeneron.
That said, while Regeneron's share price has risen, both companies still have good long-term fundamentals, and both have found ways to excel amid the coronavirus pandemic.
Image source: Getty Images.
Source Fool.com
